Prosecution Insights
Last updated: November 04, 2026
Application No. 17/385,734

COLCHICINE SALICYLATE DERIVATIVES AND METHODS OF TREATMENT

Final Rejection §103
Filed
Jul 26, 2021
Priority
Apr 17, 2015 — provisional 62/148,985 +2 more
Examiner
BARSKY, JARED
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Murray And Poole Enterprises Ltd.
OA Round
4 (Final)
50%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
476 granted / 949 resolved
-9.8% vs TC avg
Strong +23% interview lift
Without
With
+22.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
78 currently pending
Career history
1046
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
49.3%
+9.3% vs TC avg
§102
8.7%
-31.3% vs TC avg
§112
16.7%
-23.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 949 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendments Applicant’s amendments to the claims of June 1, 2026, in response to the Office Action of January 30, 2026 are acknowledged. Response to Arguments In view of the cancelation of claims as well as the filing and approval of a Terminal Disclaimer, the Double Patenting Rejections are withdrawn. In view of the amendments to the claims, the examiner has added references that are of record and were applied in rejections to parent patents applications. The examiner notes that the excipient combinations including lactose monohydrate and HPMC is taught. More specifically, a formulation taught by the prior art includes 50% alpha-lactose monohydrate and 50% HPMC 4000 mPas. See slide p33, shown below. This combination is taught to be superior for multiple reasons. The remaining excipients and percentages of excipients are rendered obvious and/or are taught by the prior art. The examiner notes that obviousness is a sliding scale. Applicant overcame the cited prior art with narrowing amendments in each of the referenced allowed patents. See Interview Summary below. Unexpected results have not been established. Interview Summary and Suggestions for Allowance: The examiner spoke with Dr. Tom Siepmann on multiple occasions and proposed an Amendment to the claims that can place this application in condition for allowance. The examiner is waiting for a response and will allow the instant claims if the product limitations can be made fully consistent in the instant claims with the allowed product claims in the parent patent claims. The distinction is that the instant claims are drawn to a salicylate salt form of claimed API. In particular, if Applicant were to incorporate the more limiting claim language of U.S. Pat. Nos. 10,610,488 or 11,648,206 into the instant claims set directed to colchicine salicylate, such claims would be allowed. Status of the Claims Claims 1, 6, 9-14, 16-19, 23, 28, 30, 31, 71, and 72 are pending. Claims 1, 6, 9-14, and 16-19 are withdrawn. Claims 23, 28, 30, 31, 71, and 72 are examined. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 23, 28, 30, 31, 71, and 72 are rejected under 35 U.S.C. 103 as being unpatentable over Unsinn et al., “Familial Mediterranean fever- a case report,” Paiatr Padol 1992;27(4):105-107 Abstract, in view of Davis et al., (US2009/0170952), in view of Marcher, "Co-Processed Lactose-based excipients for Direct Compression," November 19, 2012 (cited in IDS), and Marcher, “Retalac, a new excipient for direct compression of sustained release formulations,” http://www.pharmtech.com/meggle, July 9, 2010 (i.e., “Marcher 2010”) (cited in IDS). Unsinn teaches that colchicine-salicylate is a known salt form of colchicine used as a pharmaceutically active agent, including for chest pain. See Abstract. Unsinn teaches treating Familial Mediterranean Fever (FMF) with a single form of colchicine salt being colchicine-salicylate. Unsinn does not teach the excipient combination with colchicine-salicylate. Davis teaches a composition comprising colchicine, waxes, natural and synthetic gums as binders, including hydroxypropylmethyl cellulose (i.e., “hypromellose”) (par. 107), and lactose monohydrate (par. 115). Salts of colchicine are contemplated. See par. 42. The composition can be used to treat Familial Mediterranean Fever as a preferred condition as it is used in an example/embodiment. See par. 160. Further, the colchicine is present in an amount that comprises 0.6 mgA colchicine, wherein mgA means mg of active colchicine (par. 52). Dosage forms can also include 1/2 of the form for administration more times daily, wherein each dosage contains anywhere from 0.3 to 2.4 mgA daily (par. 160). Further, sustained release tablets are created by a coating process if desired (par. 138). One example of a tablet includes colchicine comprising about 0.6 mgA, lactose monohydrate, microcrystalline cellulose, magnesium stearate, and other excipients (par. 16). The blends are compressed to obtain a tablet (par. 23). Advantages to the composition taught by Davis include a low level of impurities, as well as minimizing the need for toxicity testing. Pregelatinized starch and sodium starch glycolate can be used (par. 16). Lubricants including PEG, magnesium stearate, polyethylene oxide, talc and others are taught (par. 111). They can be included in a concentration of 0.01 to 10 wt% (par. 112). Tableting process includes using granules that are wet, dry, milled, mixed with a disintegrant, and more. See par. 23. Davis also teaches salicylic salts forms to be acceptable. See par. 56. Stearic acid is taught as a lubricant. See par. 111. One embodiment teaches 0.6 mg colchicine (API) 0.6%, pregelatinized starch (disintegrant and filler) 12-16%, microcrystalline cellulose (disintegrant and filler) 20-24%, sodium starch glycolate (disintegrant and filler) 3.9-4.7%, magnesium stearate (lubricant) 0.5-0.7%, and lactose monohydrate (filler). See par. 16. PVP is also an acceptable agent, described by the instant application as a granulating agent. The examiner acknowledges that some picking and choosing of well-known excipients is required to arrive at the claimed excipient combinations. However, “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976)). “[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” Id. Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR at 1741. The Court emphasized that “[a] person of ordinary skill is…a person of ordinary creativity, not an automaton.” Id. at 1742. Davis teaches colchicine wherein a single dose provides a Cmax of 1.3 ng/mL and 4 ng/mL (par. 20). Further, peak concentrations generally occur in 0.5 to 2 hours (par. 11). David also teaches an immediate release formulation that releases an amount of at least 75% of the active ingredient within one hour of administration (par. 41). Further, AUC0-T occurs between 4.4 ng-hr/mL and 30.8 ng-hr/mL (par. 20). As such, a person having ordinary skill in the art could easily optimize a concentration of colchicine, which would result in the claimed Cmax, AUC0-T, and blood plasma concentrations that are claimed. According to M.P.E.P. § 2144.05, “In the case where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even if the ranges do not overlap- “Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. ‘[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.’” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). This is particularly the case because each of the claimed agents are taught and known to be result-effective variables for a particular purpose. Davis does not teach a specific combination of HPMC and lactose monohydrate, wherein the HPMC has a viscosity of 4000 mPas. Marcher explains that a formulation comprising superior properties was created by combining two excipients. One formulation comprises 50% alpha-lactose monohydrate and 50% HPMC 4000 mPas. See slide p33, shown below. PNG media_image1.png 162 404 media_image1.png Greyscale Further, the benefits of the excipient combination are explained on slide 49, shown below. PNG media_image2.png 330 591 media_image2.png Greyscale This combination is a sustained release formulation. See slide p28. Among advantages of Retalac include enabling direct compression of sustained release tablets, improved wetability of HPMC, defined and adjustable release profiles, good flowability, minimal friability, superior compressibility to physical mixture. See slide p49. Further, while some APIs are tested in the excipient formulations taught by Marcher, the excipient combination is not API dependent. See slides pp 29-35. Even further, Marcher (2010) explains lactose and HPMC are well known commonly used excipients. To overcome a tendency of HPMC to segregate and have limited flowability, a new excipient with equal parts co-processed lactose monohydrate and HPMC. The product as a result of the excipient combination demonstrates “superior functionality.” It would have been prima facie obvious to a person of ordinary skill in the art prior to the filing of the instant application to arrive at the claimed products in view of Unsinn, Davis, Marcher and Marcher2010. One would be motivated to do so because Davis teaches each of the claimed excipients with the claimed API and includes teachings that describe the well-known and result-effective nature and function of each excipient. Further, Davis teaches known salt forms to be unlimited and include the salicylate form while Unsinn teaches colchicine-salicylate as a known salt form of colchicine. Even further, a combination of equal parts lactose monohydrate and HPMC with a claimed viscosity is taught to provide an enhanced benefit. Each reference teaches treating Familial Mediterranean Fever. As such, there is a reasonable and predictable expectation of success in arriving at the claimed products in view of the cited prior art and optimizing the concentrations of known result effective variables as well as using functional equivalents to obtain the taught and readily modifiable release profile. As such, no claim is allowed. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JARED D. BARSKY whose telephone number is (571)-272-2795. The examiner can normally be reached on Monday through Friday from 8:30 to 5:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy L. Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JARED BARSKY/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Show 2 earlier events
Jun 29, 2025
Response Filed
Aug 25, 2025
Final Rejection mailed — §103
Jan 23, 2026
Request for Continued Examination
Jan 27, 2026
Response after Non-Final Action
Jan 30, 2026
Non-Final Rejection mailed — §103
Jun 01, 2026
Response Filed
Aug 28, 2026
Examiner Interview (Telephonic)
Sep 02, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774291
COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1)
3y 9m to grant Granted Oct 27, 2026
Patent 12767677
LITHIUM DIFLUORO-BIS(OXALATE)PHOSPHATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
2y 10m to grant Granted Oct 20, 2026
Patent 12740947
METHOD OF INITIATING SOTALOL HYDROCHLORIDE DOSING
3y 4m to grant Granted Sep 22, 2026
Patent 12741958
CRYSTAL FORM OF PYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR
2y 9m to grant Granted Sep 22, 2026
Patent 12723018
CINNAMOYL AMINO ACID COMPOUND AND USE THEREOF
3y 11m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
50%
Grant Probability
73%
With Interview (+22.9%)
2y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 949 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month